Literature DB >> 9860086

Features that distinguish those who die from asthma from community controls with asthma.

S C Tough1, P A Hessel, M Ruff, F H Green, I Mitchell, J C Butt.   

Abstract

To evaluate risk factors for asthma mortality, an unmatched case-control study was undertaken in the Canadian prairie provinces of Alberta, Saskatchewan, and Manitoba. Those between the ages of 5 and 50 (inclusive) who died from an acute exacerbation of asthma were compared to a control group of people with asthma from the same geographical areas who were contacted using random-digit dialing. Because no deaths occurred among residents less than 15 years old, this analysis was limited to cases and controls between 15 and 50 years old. Of the 38 deaths that occurred between November 1992 and October 1995, data were obtained from next of kin for 35 (92.1%). Of the 210 potential controls that were identified, 142 returned completed questionnaires (67.6%). Cases were more likely than controls to have asthma reported to be severe, to have experienced nocturnal symptoms, to have had cardiopulmonary resuscitation (CPR)/intubation, and to have had more healthcare utilization in the previous year. Medication use was also more common among cases compared to controls. Specific asthma triggers were reported more often for cases than controls; weather changes, excitement, depression, and stress showed the greatest case control differences. Although a number of very strong risk factors for death from asthma were identified, death from asthma is so rare in this age group that it is not possible to label an individual as "likely" to die from asthma. Nonetheless, patients, caregivers, and health professionals should be aware of indicators that would suggest greater risk.

Entities:  

Mesh:

Year:  1998        PMID: 9860086     DOI: 10.3109/02770909809048968

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  9 in total

1.  Understanding nocturnal asthma. The plot thickens.

Authors:  Reena Mehra
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

2.  Case-control study of severe life threatening asthma (SLTA) in a developing community.

Authors:  L van der Merwe; A de Klerk; M Kidd; P G Bardin; E M van Schalkwyk
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

3.  Parental psychosocial stress and asthma morbidity in Puerto Rican twins.

Authors:  Nancy E Lange; Supinda Bunyavanich; Judy L Silberg; Glorisa Canino; Bernard A Rosner; Juan C Celedón
Journal:  J Allergy Clin Immunol       Date:  2010-12-30       Impact factor: 10.793

4.  Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.

Authors:  Bradley E Chipps; Robert S Zeiger; Larry Borish; Sally E Wenzel; Ashley Yegin; Mary Lou Hayden; Dave P Miller; Eugene R Bleecker; F Estelle R Simons; Stanley J Szefler; Scott T Weiss; Tmirah Haselkorn
Journal:  J Allergy Clin Immunol       Date:  2012-06-12       Impact factor: 10.793

5.  The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis.

Authors:  Ian D Pavord; Nicola Mathieson; Anna Scowcroft; Riccardo Pedersini; Gina Isherwood; David Price
Journal:  NPJ Prim Care Respir Med       Date:  2017-03-09       Impact factor: 2.871

6.  Thoracic fluid accumulation and asthma symptoms: A new contributor mechanism.

Authors:  Cristina de Oliveira Francisco; Azadeh Yadollahi
Journal:  Porto Biomed J       Date:  2019-07-10

7.  Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort.

Authors:  Bradley E Chipps; Robert S Zeiger; Alejandro Dorenbaum; Larry Borish; Sally E Wenzel; Dave P Miller; Mary Lou Hayden; Eugene R Bleecker; F Estelle R Simons; Stanley J Szefler; Scott T Weiss; Tmirah Haselkorn
Journal:  Curr Respir Care Rep       Date:  2012-09-20

8.  An unidentified monster in the bed--assessing nocturnal asthma in children.

Authors:  Darrell Ginsberg
Journal:  Mcgill J Med       Date:  2009-01

9.  A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.

Authors:  Gennaro D'Amato; Antonello Salzillo; Amedeo Piccolo; Maria D'Amato; Gennaro Liccardi
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.